Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen (NASDAQ:CGEN) announced its upcoming presentation at ESMO 2025 in Berlin, Germany. The presentation will feature a pooled analysis of data from three Phase 1 trials evaluating COM701 in platinum resistant ovarian cancer patients.
The analysis includes data from trials testing COM701 as both monotherapy and combination therapy in heavily pretreated patients. Dr. Oladapo Yeku from Massachusetts General Hospital will present the findings on October 18, 2025 at 12:00-12:45 CEST. The poster presentation (#1196P) will subsequently be available on Compugen's website.
Compugen (NASDAQ:CGEN) ha annunciato la sua prossima presentazione al ESMO 2025 che si terrà a Berlino, Germania. La presentazione includerà un analisi combinata dei dati provenienti da tre studi di Fase 1 che valutano COM701 in pazienti con carcinoma ovarico resistente al platino.
L'analisi comprende dati da studi che testano COM701 sia come monoterapia che in terapia combinata in pazienti con pretrattamenti intensivi. Il dott. Oladapo Yeku del Massachusetts General Hospital presenterà i risultati il 18 ottobre 2025 dalle 12:00 alle 12:45 CEST. La presentazione poster (#1196P) sarà poi disponibile sul sito web di Compugen.
Compugen (NASDAQ:CGEN) anunció su próxima presentación en el ESMO 2025 en Berlín, Alemania. La presentación incluirá un análisis combinado de datos de tres ensayos de Fase 1 que evalúan COM701 en pacientes con cáncer de ovario resistente al platino.
El análisis incluye datos de ensayos que prueban COM701 tanto como monoterapia como en terapia combinada en pacientes con tratamientos previos extensos. El Dr. Oladapo Yeku del Massachusetts General Hospital presentará los hallazgos el 18 de octubre de 2025 de 12:00 a 12:45 CEST. La presentación en póster (#1196P) estará disponible posteriormente en la página web de Compugen.
Compugen (NASDAQ:CGEN)이 독일 베를린에서 열리는 ESMO 2025에서 곧 발표할 예정임을 알렸습니다. 이번 발표에서는 백금 내성 난소암 환자를 대상으로 한 3건의 1상 임상시험 데이터를 통합 분석한 결과가 소개됩니다.
분석에는 COM701을 단독요법 및 병용요법으로 투여한 다회 치료 환자의 데이터가 포함되어 있습니다. 매사추세츠 종합병원의 올라다포 예쿠 박사가 2025년 10월 18일 12:00~12:45 CEST에 연구 결과를 발표할 예정입니다. 포스터 발표(#1196P)는 이후 Compugen 웹사이트에서 확인할 수 있습니다.
Compugen (NASDAQ:CGEN) a annoncé sa prochaine présentation au ESMO 2025 à Berlin, en Allemagne. La présentation comprendra une analyse regroupée des données de trois essais de Phase 1 évaluant COM701 chez des patientes atteintes d’un cancer de l’ovaire résistant au platine.
L’analyse inclut des données d’essais testant COM701 en monothérapie et en thérapie combinée chez des patientes fortement prétraitées. Le Dr Oladapo Yeku du Massachusetts General Hospital présentera les résultats le 18 octobre 2025 de 12h00 à 12h45 CEST. La présentation sous forme de poster (#1196P) sera ensuite disponible sur le site web de Compugen.
Compugen (NASDAQ:CGEN) kündigte seine bevorstehende Präsentation auf dem ESMO 2025 in Berlin, Deutschland, an. Die Präsentation umfasst eine zusammengefasste Analyse von Daten aus drei Phase-1-Studien, in denen COM701 bei Patienten mit Platin-resistentem Eierstockkrebs untersucht wurde.
Die Analyse beinhaltet Daten aus Studien, in denen COM701 sowohl als Monotherapie als auch in Kombinationstherapie bei stark vorbehandelten Patienten getestet wurde. Dr. Oladapo Yeku vom Massachusetts General Hospital wird die Ergebnisse am 18. Oktober 2025 von 12:00 bis 12:45 Uhr MESZ vorstellen. Die Posterpräsentation (#1196P) wird anschließend auf der Website von Compugen verfügbar sein.
- None.
- None.
HOLON,
Poster details:
Title: COM701 in Ovarian Cancer: A Pooled Analysis of 3 Phase 1 Clinical Trials
Speaker: Dr. Oladapo Yeku, Massachusetts General Hospital,
Poster presentation number: 1196P
Date of poster presentation: Saturday, October 18; 12:00-12:45 CEST
The poster will be available in the publications section of Compugen's website, www.cgen.com
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to activate the immune system against cancer. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-a-pooled-analysis-of-com701-phase-1-trials-in-platinum-resistant-ovarian-cancer-at-esmo-2025-302514758.html
SOURCE Compugen Ltd.
FAQ
When and where will Compugen (CGEN) present its COM701 trial data at ESMO 2025?
What type of data will Compugen (CGEN) present at ESMO 2025?
Who will present Compugen's (CGEN) COM701 trial data at ESMO 2025?
Where can investors access Compugen's (CGEN) ESMO 2025 poster presentation?
